Etentamig

**Semantic type:** Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance

**Definition:** A T-cell engaging, human, bispecific, immunoglobulin G4 (IgG4) monoclonal antibody (T-BsAb) directed against the tumor-associated antigen (TAA) human B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17) and CD3 antigen found on T-lymphocytes, with potential immunostimulating and antineoplastic activities. Upon administration, etentamig binds to both CD3 on cytotoxic T-lymphocytes (CTLs) and BCMA found on BCMA-expressing tumor cells. This activates and redirects CTLs to BCMA-expressing tumor cells, which results in the CTL-mediated cell death of BCMA-expressing tumor cells. BCMA, a member of the tumor necrosis factor receptor superfamily that is specifically overexpressed on malignant plasma cells, plays a key role in promoting plasma cell survival. Binding to low-activating CD3 preferentially activates effector over regulatory T-cells and stimulates minimum cytokine release.

**Synonyms:** - ABBV 383 - ABBV-383 - ABBV383 - Anti-BCMA x aCD3 T-BsAb TNB-383B - Anti-BCMA x aCD3 T-cell Engaging Bispecific Antibody TNB-383B - Anti-BCMA/Anti-CD3 T-cell Engaging Bispecific Antibody ABBV-383 - Anti-alpha BCMA/Anti-alpha CD3 T-cell Engaging Bispecific Antibody TNB-383B - BCMA x CD3 T-cell Engaging Bispecific Antibody ABBV-383 - ETENTAMIG - TNB 383B - TNB-383B - TNB383B